title: [Feasibility and response of gemcitabine and carboplatin biweekly combination chemotherapy for patients with postoperative recurrence non-small cell lung cancer].
abstract: BACKGROUND
  In advanced non-small cell lung cancer(NSCLC), the standard treatment is chemotherapy with platinum doublet. Gemcitabine (GEM)is one of the major drugs administered in combination with platinum. We studied the feasibility and response of GEM and Carboplatin(CBDCA)biweekly combination chemotherapy for patients with / postoperative recurrence NSCLC.
  
  
  METHODS
  Patients received GEM(1,000 mg/m(2))over 30 minutes and CBDCA(AUC =3)over 60 minutes intravenously on day 1 biweekly. Response was evaluated with RECIST.
  
  
  RESULTS
  Between April 2005 and December 2006 thirteen patients with PS 0 or 1 were entered in the study. All patients received 4 or more cycles. Eight patients received 8 cycles. Of them, only two patients required dose-reduction for hematologic toxicity. / Grade 3/4 hematologic or non-hematologic toxicities and more than grade 2 thrombocytopenia did not occur in any patients. The overall response rate was 20%. SD was seen in 6 patients.
  
  
  CONCLUSIONS
  GEM and CBDCA biweekly combination chemotherapy is a well-tolerated regimen with promising activity against NSCLC.
authors.affiliation: Dept. of Thoracic Surgery, Aichi Cancer Center Hospital, Japan.
authors.forename: Syoichi
authors.initials: S
authors.lastname: Mori
authors.forename: Rei
authors.initials: R
authors.lastname: Kobayashi
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Okuda
authors.forename: Shizu
authors.initials: S
authors.lastname: Ogawa
authors.forename: Futoshi
authors.initials: F
authors.lastname: Ishiguro
authors.forename: Takayuki
authors.initials: T
authors.lastname: Fukui
authors.forename: Syunzo
authors.initials: S
authors.lastname: Hatooka
authors.forename: Masayuki
authors.initials: M
authors.lastname: Shinoda
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Mitsudomi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000601:surgery; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D013997:Time Factors; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D016190:Carboplatin; D000093542:Gemcitabine